Get the Stockscreener App
38.30
5.77%
2.09
Vtv Therapeutics Inc stock is traded at $38.30, with a volume of 68,381.
It is up +5.77% in the last 24 hours and down -0.56% over the past month.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
See More
Previous Close:
$36.21
Open:
$37.41
24h Volume:
68,381
Relative Volume:
1.79
Market Cap:
$150.85M
Revenue:
$17,000
Net Income/Loss:
$-31.08M
P/E Ratio:
-11.45
EPS:
-3.3463
Net Cash Flow:
$-24.86M
1W Performance:
+5.51%
1M Performance:
-0.56%
6M Performance:
+67.92%
1Y Performance:
+122.67%
1-Day Range:
$37.35
$39.00
1-Week Range:
$34.20
$39.20
52-Week Range:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
38.30 | 142.62M | 17,000 | -31.08M | -24.86M | -3.3463 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Evercore ISI | Outperform |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Jan-05-26 | Initiated | TD Cowen | Buy |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
How CRH plc stock performs during market volatility - baoquankhu1.vn
Aug Action: Does vTv Therapeutics Inc have declining or rising EPSEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Moves: Is vTv Therapeutics Inc exposed to currency risks2026 Key Highlights & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (VTVT) - Stock Traders Daily
Guidance Update: Will vTv Therapeutics Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
Published on: 2026-03-23 05:09:08 - baoquankhu1.vn
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
VTV Therapeutics (VTVT) reports $27M 2025 net loss amid cadisegliatin advancements - MSN
VTVT Forecast, Price Target & Analyst Ratings | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements - Yahoo Finance
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade - Yahoo Finance
vTv Therapeutics to Participate in the 38th Annual ROTH Conference - The Manila Times
VTv Therapeutics to Participate in the 38th Annual ROTH Conference - marketscreener.com
Biotech developing oral type 1 diabetes drug joins ROTH investor event - Stock Titan
Baker BROS. Advisors LP Has $3.46 Million Holdings in vTv Therapeutics Inc. $VTVT - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Evercore - MarketBeat
Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to "Hold" - MarketBeat
HC Wainwright Raises Earnings Estimates for vTv Therapeutics - Defense World
HC Wainwright Brokers Increase Earnings Estimates for VTVT - Defense World
HC Wainwright Forecasts Higher Earnings for vTv Therapeutics - MarketBeat
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF) - The Globe and Mail
Evercore ISI initiates vTv Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target - marketscreener.com
Evercore ISI Initiates Coverage on VTVT with Outperform Rating | VTVT Stock News - GuruFocus
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Research Analysts Set Expectations for VTVT Q1 Earnings - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving AverageShould You Sell? - MarketBeat
vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday - MarketBeat
Avoiding Lag: Real-Time Signals in (VTVT) Movement - Stock Traders Daily
BTIG Maintains Buy on vTv Therapeutics Inc (VTVT) March 11, 2026 - Meyka
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained By Investing.com - Investing.com Canada
VTVT: BTIG Reiterates Buy Rating with Unchanged Price Target | V - GuruFocus
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained - Investing.com
vTv Therapeutics 2025 – Pipeline, Clinical Trials, and Patent Portfolio Overview - Minichart
vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TipRanks
VTv Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway - TipRanks
vTv Therapeutics 2025 10-K: $0.0M Revenue, $(26.97)M Net Loss - TradingView
VTv Therapeutics: Fourth Quarter Earnings Overview - Bitget
vTv Therapeutics Inc 預計每股虧損 81 美分財報前瞻 - TradingView
VTV Therapeutics (VTVT) Quarterly & Annual Financial Results 2026News and Statistics - IndexBox
vTv Therapeutics (NASDAQ: VTVT) highlights cadisegliatin Phase 3 and new funding - Stock Titan
VTVT Stock Bolstered by Strong Financials and Strategic Advances - GuruFocus
vTv Therapeutics (VTVT) spotlights Phase 3 cadisegliatin and cash runway - Stock Titan
vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09) - TipRanks
vTv Therapeutics (VTVT) boosts cash, advances Phase 3 CATT1 trial - Stock Titan
vTv Therapeutics Q4 net loss widens on higher expenses - TradingView
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Weekly Voice
Vtv Therapeutics: Capital Efficiency and Clinical Catalysts Under Scrutiny - AD HOC NEWS
Aug Shorts: Will vTv Therapeutics Inc outperform the market in YEAREarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):